Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16473698 | 1.00 | ATM (0.54) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL14317559 | 1.00 | ATM (0.54) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL14174702 | 0.87 | ATM (0.56) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL8700454 | 0.87 | ATM (0.56) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL3656916 | 0.86 | ATM (0.52) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL3656918 | 0.86 | ATM (0.52) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL4316106 | 0.86 | ATM (0.52) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL28677738 | 0.84 | CTRB1 (0.52) | ATMCTSKCTRB1CTSSCTSL | |
| SCHEMBL24459326 | 0.84 | ATM (0.50) | ATMCTSKCTRB1ELANECTSS | |
| SCHEMBL24108374 | 0.84 | ATM (0.50) | ATMCTSKCTRB1ELANECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638017-A | Preparation method and application of chiral 4-aminopentanol | 上海华默西医药科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240239800-A1 | PYRROLO[2,3-D]PYRIMIDIN-2-ONE ANTIMICROBIAL COMPOUNDS | RIB-X PHARMACEUTICALS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-10-24 | — | — | US | disclosed |
| EP-3404028-A1 | METHODS OF MAKING ANTIMICROBIAL COMPOUNDS | Melinta Therapeutics, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2697229-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20160214988-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2016-07-28 | — | — | US | disclosed |
| US-20160214988-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2016-07-28 | — | — | US | disclosed |
| US-9221827-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221827-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221827-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015035426-A1 | ANTIMICROBIAL COMPUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MELINTA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MELINTA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MELINTA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2697229-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Melinta Therapeutics, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012173689-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012173689-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239800-A1 | PYRROLO[2,3-D]PYRIMIDIN-2-ONE ANTIMICROBIAL COMPOUNDS | LPO, MAVS, FPR2 | ATM 3965/4885CTSK 1910/4885CTRB1 2307/4885 |
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | ATM 4383/4885CTSK 153/4885CTRB1 919/4885 |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | ATM 4383/4885CTSK 153/4885CTRB1 919/4885 |
| US-20160214988-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | ATM 4458/4885CTSK 122/4885CTRB1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.